HUMAN MOLECULAR GENETICS, published by Oxford University Press, is a premier journal in the field of genetics, with an established reputation since its inception in 1992. With an impressive Q1 ranking in various categories, including Genetics, Clinical Genetics, and Molecular Biology, this journal engages a diverse readership by reporting significant advances in our understanding of the genetic basis of human health and disease. The journal has achieved notable rankings within Scopus, particularly in Clinical Genetics, making it a key resource for professionals and researchers aiming to stay at the forefront of genetic research. Although it operates under a traditional access model, it remains committed to disseminating high-quality research that informs clinical practice and enhances knowledge in the genetic field. The journal's impact factor signifies its crucial role in shaping contemporary genetic research and its application in medicine. As the field continues to evolve, HUMAN MOLECULAR GENETICS serves not only as an academic repository but also as a vital platform for innovation and discussion among students, researchers, and clinicians.

METABOLISM-CLINICAL AND EXPERIMENTAL is a premier academic journal published by W B SAUNDERS CO-ELSEVIER INC, with a distinguished history dating back to 1952. This journal serves as a vital repository of knowledge in the fields of Endocrinology, Diabetes, and Metabolism, consistently ranking in the top quartile (Q1) within these categories according to the latest metrics. With an impressive impact factor and recognized for its contributions to Biochemistry, Genetics, and Molecular Biology, it ranks #5 out of 128 in the Scopus database for Endocrinology and #11 out of 244 for Medicine related to Endocrinology, Diabetes, and Metabolism, placing it in the 95th and 96th percentiles, respectively. While the journal does not currently offer open access, it maintains rigorous peer review standards and publishes cutting-edge research that drives forward the understanding of metabolic diseases and clinical practices. By engaging with METABOLISM-CLINICAL AND EXPERIMENTAL, researchers, healthcare professionals, and students can explore groundbreaking advancements and pivotal findings that shape the future of metabolic health.

Genetic Testing and Molecular Biomarkers, an esteemed journal published by MARY ANN LIEBERT, INC, serves as a pivotal platform for advancing the field of genetic research and its applications in medicine. Focused on the innovative intersections of genetics and biomarker discovery, this journal has consistently contributed meaningful insights since its inception in 2009, with its scope evolving through 2024. With an ISSN of 1945-0265 and an E-ISSN of 1945-0257, it offers both traditional and open access options to cater to a broad audience of researchers, professionals, and students. Despite its current classification in the Q4 and Q3 quartiles for Genetics (clinical) and Medicine (miscellaneous) respectively, the journal remains committed to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in the field. As the landscape of genomic medicine continues to expand, Genetic Testing and Molecular Biomarkers is positioned as a crucial resource for disseminating cutting-edge discoveries and fostering interdisciplinary collaboration.

Epigenomes is a distinguished open access journal published by MDPI, dedicated to advancing the field of epigenetics and its interdisciplinary connections to biochemistry, genetics, and molecular biology. Since its inception in 2017, this journal has provided a transparent platform for researchers to share their findings, contributing to a deeper understanding of epigenetic mechanisms and their implications in health, toxicology, and mutagenesis. Ranked in the Q2 quartile across multiple categories, including biochemistry and genetics, Epigenomes is recognized for its scholarly contributions, reflected in its notable Scopus rankings. Readers benefit from a wealth of open access articles, fostering innovation and collaboration within the academic community. With its headquarters in Switzerland and an unwavering commitment to scientific rigor, Epigenomes is positioned as a vital resource for researchers, professionals, and students seeking to deepen their insights into the epigenomic landscape.

The Indian Journal of Clinical Biochemistry, published by SPRINGER INDIA, serves as a pivotal platform for researchers and professionals in the field of clinical biochemistry. With an ISSN of 0970-1915 and E-ISSN 0974-0422, this esteemed journal has been disseminating high-quality research since its inception in 1986. As a Q3 ranked journal in Clinical Biochemistry according to the 2023 category quartiles, it occupies a significant position within the realm of biochemistry, genetics, and molecular biology—ranked #61 out of 117 in Scopus. The journal's scope emphasizes the advancement of knowledge and practices in clinical diagnostics, aiming to bridge the gap between laboratory research and clinical application. Positioned in the vibrant academic landscape of India, the Indian Journal of Clinical Biochemistry is a crucial resource for students, researchers, and professionals seeking to stay abreast of the latest trends and innovations in the field, thus fostering the development of clinical biochemistry both nationally and globally.

Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

Epigenetics & Chromatin, published by BMC, is a leading open-access journal that has been at the forefront of research in the fields of genetics and molecular biology since its inception in 2008. With an impressive Q1 category ranking in both Genetics and Molecular Biology as of 2023, this journal is pivotal for researchers and professionals aiming to explore the complexities of gene regulation and chromatin dynamics. The journal is renowned for its commitment to disseminating high-quality research, featuring diverse articles ranging from original research to comprehensive reviews. It enjoys a significant impact within the academic community, evidenced by its Scopus rankings that place it among the top 30% of journals in Genetics and the top 40% in Molecular Biology. With a dedicated open-access model, Epigenetics & Chromatin ensures that its comprehensive content is readily accessible to researchers globally, fostering collaboration and innovation across the scientific landscape. Located in the UK, the journal continues to attract a diverse audience of scholars and practitioners passionate about understanding the intricate layers of epigenetic regulation.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

EUROPEAN JOURNAL OF ENDOCRINOLOGY, published by Oxford University Press, stands as a premier international platform dedicated to advancing research in the burgeoning field of endocrinology, diabetes, and metabolism. Since its inception in 1994, this esteemed journal has gained recognition for its rigorous peer-reviewed articles and innovative studies, evidenced by its impressive Q1 rankings across multiple categories, including Endocrinology and Medicine. With a focus on disseminating critical findings and fostering interdisciplinary collaboration, the journal ranks 33rd out of 244 in Endocrinology, Diabetes, and Metabolism, and 20th out of 128 in Biochemistry, Genetics, and Molecular Biology according to Scopus metrics, positioning it in the top percentiles for researchers worldwide. Although it does not offer open access, the journal remains a vital resource for academics and practitioners alike who seek to stay at the forefront of endocrine research. The EUROPEAN JOURNAL OF ENDOCRINOLOGY continues to push the boundaries of knowledge, driving forward the understanding of complex hormonal functions and their clinical implications.

GENE, an esteemed journal published by Elsevier, serves as a vital resource for researchers and professionals in the fields of genetics and medicine. With an ISSN of 0378-1119 and an E-ISSN of 1879-0038, this scholarly journal has been at the forefront of genetic research since its inception in 1976 and is set to continue until 2025. Situated in the Netherlands, GENE is recognized for its significant contributions, reflected in its Q2 ranking in both Genetics and Miscellaneous Medicine categories for 2023. This positioning within the Scopus rankings demonstrates its impact and relevance in a competitive field, where it holds the rank of #129 out of 347 in Genetics, placing it within the 62nd percentile. Although it does not offer open access options, GENE provides invaluable insight into contemporary genetic research, thereby fostering academic discussions and advancements. Researchers, professionals, and students alike will find GENE an essential platform for disseminating knowledge and exploring innovative developments in genetics and associated sciences.